Enhanced Antigen-Specific Antibody and Cytokine Responses When Targeting Antigen to Human FcGAMMA Receptor Type I Using an Anti-Human FcGAMMA Receptor Type I-Streptavidin Fusion Protein in an Adjuvant-Free System

There is a continuing need for alternatives to current human adjuvants. Recombinant protein vaccines, which target antigen to human Fc gamma receptor type I (hFcγRI) on hFcγRI-expressing antigen presenting cells, provide one potential alternative. Using a recombinant anti-hFcγRI-antigen fusion prote...

Full description

Saved in:
Bibliographic Details
Published in:Immunological investigations 2005, Vol.34 (4), p.417-429
Main Authors: Adamova, Elisaveta, Walsh, Mary C., Gosselin, Diane R., Hale, Karen, Preissler, Mark T., Graziano, Robert F., Gosselin, Edmund J.
Format: Article
Language:English
Subjects:
Adjuvant
Adjuvants, Immunologic - genetics
Animals
Antibody Formation
Antigens - immunology
Cytokines - biosynthesis
Fc receptor
Humans
Immune response
Immunization
Immunoglobulin Variable Region - genetics
Immunoglobulin Variable Region - immunology
Male
Mice
Mice, Inbred C57BL
Receptors, IgG - immunology
Recombinant Fusion Proteins - immunology
Streptavidin
Streptavidin - genetics
Streptavidin - immunology
Vaccine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a continuing need for alternatives to current human adjuvants. Recombinant protein vaccines, which target antigen to human Fc gamma receptor type I (hFcγRI) on hFcγRI-expressing antigen presenting cells, provide one potential alternative. Using a recombinant anti-hFcγRI-antigen fusion protein and adjuvant independent mouse model, we demonstrate enhanced antigen-specific antibody responses to low doses of antigen, when targeting antigen to hFcγRI in vivo. Enhanced antibody production to hFcγRI-targeted antigen is evident in both primary and secondary immune responses, as compared to that of non-targeted antibody. Furthermore, antigen isotype and cytokine responses following immunization with hFcγRI-targeted antigen, suggest enhancement of both Th1 and Th2 responses.
ISSN:0882-0139
1532-4311
DOI:10.1080/08820130500265372